These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 31049142

  • 21. Hypolipidemic potential of Lepidogrammitis drymoglossoides in high-fat diet fed mice.
    Lei Y, Chen J, Cai Y, Xiong C, Ruan J.
    Int J Cardiol; 2011 Mar 03; 147(2):323-5. PubMed ID: 21247642
    [No Abstract] [Full Text] [Related]

  • 22. The Ideal Lipid Report: A Need for Consensus.
    Pedro-Botet J, Rodríguez-Padial L, Brotons C, Esteban-Salán M, García-Lerín A, Pintó X, Lekuona I, Ordóñez-Llanos J.
    Rev Esp Cardiol (Engl Ed); 2018 Jul 03; 71(7):512-514. PubMed ID: 29716842
    [No Abstract] [Full Text] [Related]

  • 23. [KLAS [Kanazawa Lipid Assessment Survey]].
    Mabuchi H, Inazu A, Higashikata T, Nohara A, Koizumi J.
    Nihon Rinsho; 2001 Mar 03; 59 Suppl 3():469-76. PubMed ID: 11347115
    [No Abstract] [Full Text] [Related]

  • 24. Cardiovascular risk assessment and lipid modification: NICE guideline.
    Duerden M, O'Flynn N, Qureshi N.
    Br J Gen Pract; 2015 Jul 03; 65(636):378-80. PubMed ID: 26120133
    [No Abstract] [Full Text] [Related]

  • 25. Pharmacological treatment of hypertension and hyperlipidemia in Izhevsk, Russia.
    Cybulsky M, Cook S, Kontsevaya AV, Vasiljev M, Leon DA.
    BMC Cardiovasc Disord; 2016 Jun 03; 16():122. PubMed ID: 27255373
    [Abstract] [Full Text] [Related]

  • 26. Drug therapy for hyperlipidemia. When reducing cardiovascular risk is a priority.
    Bays HE, Dujovne CA.
    Postgrad Med; 1992 Apr 03; 91(5):162-4, 167-8, 171-2 passim. PubMed ID: 1561158
    [Abstract] [Full Text] [Related]

  • 27. [Update of lipid lowering therapy].
    Riesen WF, Mordasini RC.
    Praxis (Bern 1994); 2008 Nov 05; 97(22):1179-84. PubMed ID: 18979436
    [Abstract] [Full Text] [Related]

  • 28. Development of proprotein convertase subtilisin/kexin type 9 inhibitors and the clinical potential of monoclonal antibodies in the management of lipid disorders.
    Gupta S.
    Vasc Health Risk Manag; 2016 Nov 05; 12():421-433. PubMed ID: 27877050
    [Abstract] [Full Text] [Related]

  • 29. Association between achieving treatment goals for lipid-lowering and cardiovascular events in real clinical practice.
    Lindgren P, Borgström F, Stålhammar J, Alemao E, Yin DD, Jönsson L.
    Eur J Cardiovasc Prev Rehabil; 2005 Dec 05; 12(6):530-4. PubMed ID: 16319541
    [Abstract] [Full Text] [Related]

  • 30. PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab.
    Blom DJ, Dent R, Castro RC, Toth PP.
    Vasc Health Risk Manag; 2016 Dec 05; 12():185-97. PubMed ID: 27274264
    [Abstract] [Full Text] [Related]

  • 31. Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance.
    Rabar S, Harker M, O'Flynn N, Wierzbicki AS, Guideline Development Group.
    BMJ; 2014 Jul 17; 349():g4356. PubMed ID: 25035388
    [No Abstract] [Full Text] [Related]

  • 32. Managing the dyslipidemia of metabolic syndrome: beyond statin therapy.
    Jialal I, Smith G.
    Metab Syndr Relat Disord; 2012 Jun 17; 10(3):159-60. PubMed ID: 22568574
    [No Abstract] [Full Text] [Related]

  • 33. Lipoprotein(a) risk in women and efficacy of ascorbate.
    Bostom AG.
    JAMA; 1994 Oct 19; 272(15):1169. PubMed ID: 7933344
    [No Abstract] [Full Text] [Related]

  • 34. Implications of 4S evidence on baseline lipid levels.
    Durrington PN.
    Lancet; 1995 Jul 15; 346(8968):181. PubMed ID: 7661979
    [No Abstract] [Full Text] [Related]

  • 35. [Helsinki Heart Study].
    Sekiya M, Ishibashi S.
    Nihon Rinsho; 2001 Mar 15; 59 Suppl 3():404-9. PubMed ID: 11347103
    [No Abstract] [Full Text] [Related]

  • 36. Interview of William Kannel, MD. Interview by Peter Wilson, Henry Greenberg.
    Kannel W.
    Prog Cardiovasc Dis; 2010 Mar 15; 53(1):4-9. PubMed ID: 20620419
    [No Abstract] [Full Text] [Related]

  • 37. Lipidology.
    Nicholls SJ.
    Cardiol Clin; 2018 May 15; 36(2):xiii. PubMed ID: 29609763
    [No Abstract] [Full Text] [Related]

  • 38. [Fibrate influence on lipids and insulin resistance in patients with metabolic syndrome].
    Idzior-Waluś B.
    Przegl Lek; 2001 May 15; 58(10):924-7. PubMed ID: 11957820
    [Abstract] [Full Text] [Related]

  • 39. Ciprofibrate and lipid profile.
    Chandler HA, Batchelor AJ.
    Lancet; 1994 Jul 09; 344(8915):128-9. PubMed ID: 7912363
    [No Abstract] [Full Text] [Related]

  • 40. Should separate endpoint trials be required for all lipid-lowering drugs acting by the same mechanism?
    Shepherd J, Olsson AG, Sacks FM, Black DM, Orloff DG, Bilheimer DW.
    Am J Cardiol; 1998 Apr 23; 81(8A):88F-94F. PubMed ID: 9604922
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.